Eli Lilly touts some mixed PhIII results for cluster headaches as Amgen, Novartis prep a market-busting move in migraine
With Amgen and Novartis eagerly awaiting their PDUFA date for the leading CGRP migraine drug Aimovig later this week, Eli Lilly is stepping up with some mixed Phase III results for its own contender in the field.
In a hit and a miss, Lilly researchers say that galcanezumab scored on the primary endpoint in a Phase III study of patients suffering from episodic, weekly cluster headaches. Placed up against a placebo, their drug achieved a statistically significant reduction in cluster attacks — though the p value of 0.036 was a long way from a standout grade.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters